Fiztasovimab (NPC-21, EV2038) is a fully human IgG1lambda mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV[1].
Molecular Weight:
(144.49 kDa)
Purity:
96.49
CAS Number:
[2467411-25-0]
Target:
CMV
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted